斯托克治疗公司宣布,其针对Dravet综合征的在研药物Zorevunersen,其III期关键临床试验EMPEROR研究已完成全部162名患者的入组工作。这一里程碑标志着该候选疗法向潜在上市又迈进了关键一步。
斯托克治疗公司宣布,其针对Dravet综合征的在研药物Zorevunersen,其III期关键临床试验EMPEROR研究已完成全部162名患者的入组工作。这一里程碑标志着该候选疗法向潜在上市又迈进了关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.